drugset / Trial / NCT02895191
The Safety and Dose Response Relationship of Ulinastatin for Acute Respiratory Distress Syndrome(ARDS)
Phase 2
Unknown
60 enrolled
Techpool Bio-Pharma Co., Ltd.
The First Affiliated Hospital of Guangzhou Medical University · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Compared with placebo, evaluate the effects and safety of Ulinastatin(UTI) added to conventional treatment for ARDS; Evaluate the dose response relationship of Ulinastatin for ARDS.
Timeline
- Start
- 2016-08
- Primary completion
- 2019-09
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ulinastatin | Protein / enzyme biologic | 1.2e+06 iu | — |
| Subject | Ulinastatin | Protein / enzyme biologic | 2.4e+06 iu | — |
| Subject | Ulinastatin | Protein / enzyme biologic | 4.8e+06 iu | — |